Shenzhen JYMed is a high-tech enterprise engaged in research and development, manufacturing and commercialization of peptides and related products including active pharmaceutical ingredient peptides, cosmetic peptides and new peptide drugs.Shenzhen JYMed has built an R&D center and two major production bases. The total production capacity of chemically synthesized peptides has reached several tons annually, positioning the company at the forefront of the industry.
Shenzhen JXBio Pharmaceutical Co., Ltd.(Shenzhen JXBio) is a wholly-owned subsidiary of Shenzhen JYMed Technology Co., Ltd. (JYMed). It is an innovative pharmaceutical company that integrates the research & development, production and sales of peptide drugs and has independent intellectual property rights. Shenzhen JXBio was established in 2013 with a registered capital of 30 million yuan. The main product lines include freeze-dried powder injection, non-terminally sterilized small-volume injection (including cassette) and sustained-release microsphere production line. Shenzhen JXBio 's products, technology, talents and hardware facilities are in a leading position in the domestic biomedical field.
Hubei JXBio Pharmaceutical Co., Ltd.(Hubei JXBio) is a wholly-owned subsidiary of Shenzhen JYMed Technology Co., Ltd. (JYMed).Hubei JXBio is located in Hubei Xian'an Economic Development Zone with a total investment of RMB 900 million. It has 18 new peptide drug production bases that meet the US, EU and Chinese cGMP standards. The company is committed to better meeting the needs of society and the market for high-end pharmaceutical products. Based on knowledge and talents, the company continuously strengthens the company's independent innovation capability and enhances its core competitiveness.